{
    "clinical_study": {
        "@rank": "8254", 
        "arm_group": [
            {
                "arm_group_label": "Octaplas", 
                "description": "Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures"
            }, 
            {
                "arm_group_label": "standard plasma products", 
                "description": "Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess and evaluate the safety of octaplas\u2122 in comparison to standard plasma product\n      (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of\n      thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange,\n      with a special emphasis on the occurrence of thromboembolic events (TEEs)."
        }, 
        "brief_title": "Octaplas Adult TTP Trial", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Thrombotic Thrombocytopenic Purpura", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombotic Thrombocytopenic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient is a male or female at least 18 years of age or older.\n\n          2. Patient has a diagnosis of TTP or suspicion of TTP that is planned on being treated\n             with TPE within 3 days of study entry.\n\n          3. Patient has thrombocytopenia (platelets < 100 x 10P9P/L).\n\n          4. Patient is willing to give voluntary written informed consent before any\n             study-related procedure is to be performed that is not part of standard medical care,\n             with the understanding that consent may be withdrawn by the subject at any time\n             without prejudice to future medical care.\n\n        Exclusion Criteria:\n\n          1. Patient has a history of severe hypersensitivity reaction to plasma-derived products\n             or to FFP.\n\n          2. Patient has an already known IgA deficiency with documented antibodies against IgA.\n\n          3. Patient is currently participating in an interventional clinical study or has\n             participated during the past 1 month prior to study inclusion.\n\n          4. Patient has severe deficiencies of Protein S.\n\n          5. Patient has a history of TTP relapse.\n\n          6. Patient received more than 1 treatment of plasma exchange or plasma infusion for\n             current episode of TTP prior to randomization.\n\n          7. Patient received treatment for TTP within previous 6 months.\n\n          8. Patient is currently taking ACE-inhibitors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients undergoing Plasma exchange for Thrombotic Thrombocytopenic Purpura"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938404", 
            "org_study_id": "LAS-214"
        }, 
        "intervention": {
            "arm_group_label": "Octaplas", 
            "intervention_name": "Octaplas", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Plasma exchange", 
            "Thrombotic Thrombocytopenic Purpura", 
            "TTP"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania"
                }, 
                "name": "University of Pennsylvania"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Post-Marketing Requirement Study to Evaluate the Safety and Efficacy of Octaplas\u2122 in Patients With Thrombotic Thrombocytopenic Purpura With Special Emphasis on Monitoring the Occurrence of Thromboembolic Events", 
        "overall_contact": {
            "email": "michael.eppolito@octapharma.com", 
            "last_name": "Michael Eppolito, MBA"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number of TEEs reported", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 28 days followed by a 24 hour follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The frequency of TEEs reported", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days followed by a 24 hour follow-up"
            }, 
            {
                "measure": "Investigator Responses to the efficacy rating scale", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days followed by a 24 hour follow-up"
            }, 
            {
                "measure": "Number of Serious ADRs reported", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days followed by a 24 hour follow-up"
            }
        ], 
        "source": "Octapharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Octapharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}